Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Daniel E. Spratt
Historically, prostate biopsy was performed using only systematic, template-based sampling.1 Prostate magnetic resonance imaging (MRI) followed by targeted biopsy of lesions suggestive of malignant neoplasm has emerged as a major advance in prostate cancer diagnosis, with several randomized clinical trials establishing superiority over systematic-only approaches.2-4 For men with prior negative biopsy results and persistent concern for cancer, prebiopsy MRI was substantiated even earlier,5...
How Well Do AI Risk Estimates Match Real-World Prostate Cancer Outcomes?
Opinion|Videos|October 9, 2026 (Updated: October 9, 2026) How Well Do AI Risk Estimates Match Real-World Prostate Cancer Outcomes? Daniel Spratt, MD, reviews how closely MMAI-predicted 10-year distant metastasis and prostate cancer–specific mortality tracked observed STAR-CAP outcomes, including among patients treated with surgery.
Evaluating AI Tools for Prostate Cancer: What Urologists Should Ask
Opinion|Videos|October 9, 2026 (Updated: October 9, 2026) Evaluating AI Tools for Prostate Cancer: What Urologists Should Ask Daniel Spratt, MD, outlines the validation standards urologists should expect before adopting AI-based tools, where AI-driven digital pathology is headed, and his key takeaway from the benchmarking data.
Using AI Risk Estimates in Prostate Cancer Treatment Decisions
Opinion|Videos|October 9, 2026 (Updated: October 9, 2026) Using AI Risk Estimates in Prostate Cancer Treatment Decisions Daniel Spratt, MD, explains how he layers MMAI results onto NCCN risk groups and how he manages discordant results in both directions.
Benchmarking AI Risk Estimates in Prostate Cancer Against STAR-CAP
Opinion|Videos|October 9, 2026 (Updated: October 2, 2026) Benchmarking AI Risk Estimates in Prostate Cancer Against STAR-CAP Daniel Spratt, MD, explains what the STAR-CAP cohort is, what an MMAI risk estimate represents, and why calibration benchmarking differs from clinical validation.
Closing Risk Stratification Gaps in Localized Prostate Cancer With AI
Opinion|Videos|October 2, 2026 (Updated: October 2, 2026) Closing Risk Stratification Gaps in Localized Prostate Cancer With AI Daniel Spratt, MD, outlines the limitations of PSA-, T stage-, and Gleason-based risk stratification and explains how AI-derived, continuous risk estimates could address them. Welcome back to another Urology Times Special Report.
ASTRO 2026: Role of Biomarkers in the Post-operative Setting for Prostate Cancer
(UroToday.com) The 2026 ASTRO annual meeting featured a use of novel biomarkers in GU cancers session and a presentation by Dr. Daniel Spratt discussing the role of biomarkers in the post-operative setting for prostate cancer. Dr. Spratt began his presentation by looking back at the state of prostate cancer care over the last decade.
ASTRO 2026: Benchmarking Multimodal AI-Predicted Metastasis and Prostate Cancer-Specific Mortality Risk Against STAR-CAP: A 20,000-Patient Commercial Experience
(UroToday.com) The 2026 ASTRO annual meeting featured a poster session and a presentation by Dr. Daniel Spratt discussing multimodal artificial intelligence (MMAI) and prediction of metastasis and prostate cancer specific mortality risk against STAR-CAP. The commercial MMAI digital pathology–based prognostic biomarker for biopsy specimens provides individualized 10-year distant metastasis risk estimates, categorized as MMAI low (<3%), intermediate (3–10%), and high (>10%).
ASTRO 2026: Effectiveness and Safety of Relugolix in Patients With Advanced Prostate Cancer Receiving Radiation Therapy: 6-Month Subgroup Analysis of the OPTYX Study
(UroToday.com) The 68th Annual American Society for Radiation Oncology (ASTRO) Annual Meeting held in Boston, MA was host to a poster presentation by Dr. Daniel Spratt and colleagues evaluating the effectiveness and safety of relugolix among patients receiving concurrent radiation therapy (RT) in real-world clinical practice.
Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer : A Randomized Clinical Trial
|
Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial Supplement 1. Supplement 2. eTable 1. Cox Proportional Hazards Model of Disease-Free Survival eTable 2. Cox Proportional Hazards Model of Overall Survival eTable 3. Cox Proportional Hazards Model of Biochemical Failure eTable 4. Protocol-Specified Adverse Events (AEs) eFigure 1. Mean EPIC Urinary Irritative/Obstructive Domain Across Time eFigure 2.
By Rodney Ellis, Stephanie Pugh, James Yu, Felix Feng, Andre Konski, Robert L. Grubb, Robert Wallace, David J. Gladstone, Cynthia Ménard, Joseph A. Miccio, Jeff M. Michalski, Daniel E. Spratt, Alvaro Martinez Verified, Álvaro Valadés Martínez Verified, Scott Morgan, Alina Mihai, Abhishek Solanki, Asim Amjad, Michael Straza, Guila Delouya, Thomas Schroeder, David Marshall, Nirav S. Kapadia, Akshar Patel, Ali El-Gayed, Rebecca Paulus, Howard M. Sandler, Arthur J. Frazier, J. Daniel Pennington, Terrence P. Cescon, Harold A. Yoon
|
JAMA: Journal of the American Medical Association
Verified
The Emperor’s New Clothes—The Discipline of Evidence
Hans Christian Andersen’s “The Emperor’s New Clothes” endures because an entire court learned to praise what it could not see.1 The fable warns that when prestige, novelty, and social pressure line up together, the absence of evidence can be mistaken for evidence of excellence. In the end, it took a child, untouched by those pressures, to say plainly that the emperor was in fact naked. Prostate cancer care is unfortunately highly vulnerable to the same error.
How positive was PROTEUS? Reconsidering success when most patients never reach no evidence of disease
PROTEUS met its amended co-primary end points but should not be interpreted as practice changing. The trial compared two experimental strategies rather than the current standard of care, relied on an unvalidated approach (prostate-specific membrane antigen-PET) for assessments of metastasis-free survival, demonstrated minimal absolute benefit with increased toxicity and lacks both mature overall survival data and sufficient data on patient-reported outcomes to support adoption.
Preliminary results from PRIMARY2: bringing colour to a grey arena
FREE with registration! Log in or register to access the full article. References 1. Kasivisvanathan, V ∙ Rannikko, AS ∙ Borghi, M ∙ et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis N Engl J Med. 2018; 378:1767-1777 2. European Association of Urology EAU guidelines on prostate cancer2026 3. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology: prostate cancer early detection, version 2.2026 4. Buteau, JP ∙ Moon, D ∙ Fahey, MT ∙ et al.
EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression
|
Abstract Androgen deprivation therapy (ADT) + androgen receptor pathway inhibitor (ARPI) ± docetaxel represent the standard of care in patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, some patients still have early progression (EP). EMETPRO is a multicentric, retrospective registry of patients with EP mHSPC. Patients with EP mHSPC were defined as patients who had progression ≤6 months under ADT+docetaxel or ADT + ARPI or ≤9 months from ADT monotherapy start.
By Fabio Turco, Silke Gillessen, Giuseppe Salfi, Niven Mehra, Matthew Labriola, Daniel George, Amanda Broderick, Anna Patrikidou, Consuelo Buttigliero, Veronica Crespi, Hirotsugu Uemura, Kazutoshi Fujita, Takanobu Utsumi, Hiroyoshi Suzuki, Daniele Raggi, Umberto Basso, Rafael Morales-Barrera, Cora Sternberg, Daniela Guevara, Orazio Caffo, Giuseppe Procopio, Andrea Zivi, Sara Merler, Daniel E. Spratt, Pedro Barata, Carlo Messina, Yuksel Urun, Hatice Bolek, Ignacio Duran, Nieves Martinez Chanzá, Lisa G Horvath, Rhiannon Mellor, Sabrina Rossetti, Richard Cathomas, Giuseppe Banna, Vincenza Conteduca, Margaret Ottaviano, Laura Marandino, Hui-Ming Lin, Luigi Tortola, Ricardo Mestre, Martino Pedrani, Iris S. H. Kloots, Peter H. J. Slootbeek, Hortense Patry, David Marmolejo Castaneda, Mariella Sorarù, Merve Bengisu Soykök
|
Nature
Verified
Elective Nodal Radiotherapy in Localized Prostate Cancer: A Meta-Analysis
Get full text access Log in, subscribe or purchase for full access. References 1. Koontz, B.F. ∙ Pra, AD. Shifting the Curtain—Can We Make Sense of the Whole Pelvis Controversy? Int J Radiat Oncol Biol Phys. 2020; 106:534-536 2. Patel, S.A. ∙ Liu, Y. ∙ Solanki, A.A. ... Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer Urologic Oncology: Seminars and Original Investigations. 2023; 41:325 e15-325.e23 3. Wortman, B.G. ∙ Creutzberg, C.L. ∙ Putter, H. ...
APCCC 2026: Are There Patients with PSA Recurrence Who Do Not Need Imaging and Treatment?
(UroToday.com) The 2026 APCCC meeting featured a treatment of PSA recurrence session and a presentation by Dr. Daniel Spratt discussing whether there are patients with PSA recurrence who do not need imaging and treatment.
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial
What does this study add? This study demonstrates that incorporating pembrolizumab into trimodality bladder-preservation therapy is feasible and can achieve high pathologic complete response rates, suggesting meaningful antitumor activity. Importantly, while the 2-yr bladder-intact disease-free survival did not surpass the predefined threshold, durable metastasis-free and overall survival outcomes were observed.
Transcriptomic analysis to uncover the mechanism of radiosensitization of AR-positive triple-negative breast cancers with AR inhibition - npj Breast Cancer
|
Abstract The androgen receptor (AR) has been identified as a driver of tumor growth and radioresistance in triple-negative breast cancers (TNBC), though the mechanistic role of AR in response to radiation therapy (RT) remains unknown. Here, we demonstrate that inhibition with the second-generation anti-androgen, apalutamide, but not darolutamide, is sufficient to radiosensitize AR+ TNBC models (rER: 1.34-1.41; rER: 0.96-1.11, respectively).
By Breanna McBean, Benjamin J. Hauk, Anna R. Michmerhuizen, Benjamin Chandler, Andrea M Pesch, Lynn M. Lerner, Douglas Gurdak, Connor Ward, Priyanka Rana, Reine Abou Zeidane, Vesna Mercer, Mingfang Tao, Ethan Hochmuth, Kassidy M. Jungles, Stephanie Green the, Meilan Liu, Daniel E. Spratt, Alan Boyle Verified, Lori J. Pierce, Corey Speers
|
Nature
Verified
Randomized Clinical Trial Led by University Hospitals Seidman Cancer Center Oncologist Leads to Practice-Changing Precision Prostate Cancer Therapy
Randomized trial validates first biomarker tool to guide hormone treatment decisions, allowing for more personalized prostate cancer care Patients with a prostate tumor subtype known as luminal B had much lower risks of recurrence and metastasis when radiation was complemented by apalutamide First-of-its-kind genomic test (PAM50), Decipher Enabled Biomarker by Veracyte, determines prostate cancer subtype Once subtype is determined by test; treatment can be personalized Originally developed to...
Continuing the Focal Fallacy
Get full text access Log in, subscribe or purchase for full access. References 4. Hamdy, F.C. ∙ Donovan, J.L. ∙ Lane, J.A. ... Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer N Engl J Med. 2023; 388:1547-1558 5. Yu, J.B. ∙ DeStephano, D.M. ∙ Jeffers, B. ... The comparative toxicity of focal ablation versus intensity modulated radiation therapy for prostate cancer Int J Radiat Oncol Biol Phys. 2025 Sep 23; S0360-3016(25)06282-0 6. Van As, N. ∙ Griffin, C.
Time to Treatment Initiation for the 30 Most Prevalent Cancer Types: Trends and Predictors of Change
Authors retain all rights in any data supplements associated with their articles. The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in this Data Supplement should not be construed as an endorsement of the products mentioned.
Lessons from Radiation Oncology: How Can We Improve PSMA RLT? "Presentation" - Daniel Spratt
Read the Full Video Transcript Daniel Spratt: Appreciate the invitation, once again, to speak to you guys. This is the topic given to me: What lessons from radiation oncology can you guys use to improve PSMA RLT? So to start, I’m going to—well, that last talk was actually fantastic, and one of the best in terms of using this correctly—but I’m going to actually challenge you a little bit more.
Can We Kill the Bone Scan? "Presentation" - Daniel Spratt
Read the Full Video Transcript Daniel Spratt: All right. Thanks. I'm Dan Spratt. So none of my comments today reflect any of my roles on the NCCN or the FDA, although they are my personal beliefs. Can we kill the bone scan? None of this is relevant. I don't get funded for bone scans. So what’s the role of diagnostic tests in medicine? So there’s diagnostic imaging, there’s prognostic imaging at its core. Other than for diagnosis, we do imaging to do TNM staging.
The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancer
ABSTRACT Relugolix is a once-daily oral gonadotropin-releasing hormone antagonist that was approved by the U.S. Food and Drug Administration in 2020 for the treatment of advanced prostate cancer. Relugolix is commonly co-prescribed with complementary oncologic therapies or agents targeting associated comorbidities (e.g. cardiovascular disease).
Combining Genomic Classifier and Digital Pathology Artificial Intelligence in Prostate Cancer Risk Stratification - Daniel Spratt
Read the Full Video Transcript Zachary Klaassen: Hi. My name is Zach Klaassen. I'm a urologic oncologist at the Georgia Cancer Center. And I am delighted to be joined on UroToday by Dr. Dan Spratt, who is a radiation oncologist and chair of the department, University Hospitals Seidman Cancer Center, Case Western Reserve University. Dan, thanks so much for joining us on UroToday. Daniel Spratt: Thank you so much for having me. It's always a pleasure.
Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer | Prostate Cancer and Prostatic Diseases
Abstract Patients treated with RT and long-term androgen deprivation therapy (ltADT) for high-risk localized prostate cancer (HRLPC) with 1 high-risk factor (any of Gleason ≥8, PSA > 20 ng/mL, ≥cT3; “high-risk”) have better outcomes than those with 2–3 factors and/or cN1 disease (“very high risk”). We evaluated whether this risk stratification could determine benefit from ltADT versus short-term (stADT).
Genomic Classifiers and Artificial Intelligence (AI) as Predictors for Treatment Benefit "Presentation" - Daniel Spratt
Read the Full Video Transcript Daniel Spratt: So I'm hyper-simplifying the NCCN guidelines for what I'm going to talk about today—decisions of when we add short-term hormone therapy, long-term hormone therapy, and now a consideration of Abiraterone. And the basis—what is the primary biomarker in NCCN risk group? So it's a Gleason score, and this is the Gleason system taken from the work from about 60 years ago based upon seven PCSM events.
In Patients Who Receive Salvage Radiation Therapy For BCR, Who Needs Additional Systemic Therapy, What and For How Long?" Presentation" - Daniel Spratt
Read the Full Video Transcript Daniel Spratt: Now we're talking post-operative; the guy chose to have surgery and he's had a biochemical recurrence. So should we add systemic therapy? What type and for how long? So as you've heard briefly, four of the primary phase III randomized trials have been discussing at least using hormone therapy.
Hypoxia-associated gene signatures are not prognostic in high-risk localised prostate cancers undergoing androgen deprivation therapy with radiotherapy
Keywords prostate cancer biochemical recurrence hypoxia androgen deprivation therapy Introduction Prostate cancer (PCa) is diagnosed in 1.4 million men globally each year and causes 375,000 deaths, making PCa the second-most common cancer and fifth-most common cause of cancer death in men [1]. Patients are stratified by clinical parameters such as blood prostate-specific antigen (PSA) levels, tumour T-stage and histopathological Gleason grade group into low, intermediate, and high-risk PCa [2].
Erratum
⁎Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio †Veracyte, Inc, South San Francisco, California ‡Department of Radiation Oncology, Washington University, St. Louis, Missouri §Princess Margaret Cancer Centre, Cancer Clinical Research Unit, Toronto, Ontario, Canada ‖Department of Pathology, UCSF Medical Center-Mount Zion, San Francisco, California ¶Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston,...
A step closer to the use of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer
Get full text access Log in, subscribe or purchase for full access. References 1. Sartor, O ∙ de Bono, J ∙ Chi, KN ∙ et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer N Engl J Med. 2021; 385:1091-1103 2. Hofman, MS ∙ Emmett, L ∙ Sandhu, S ∙ et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial Lancet. 2021; 397:797-804 3.
Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized Trials
The number of therapeutic options continues to increase for men with high-risk localized prostate cancer [ 1 National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Prostate cancer v4.2023. ]. Risk stratification within a given National Comprehensive Cancer Network (NCCN) risk group remains challenging [ 2 Dess R.T. Suresh K. Zelefsky M.J. et al.
Personalizing Salvage Radiation and Hormone Therapy for Biochemical Recurrence - Daniel Spratt
Read the Full Video Transcript Alicia Morgans: Hi, I'm so excited to be here today with Professor Dan Spratt, who is joining me from Case Western Reserve University and the Seidman Cancer Center, as well as joining me recently in Lugano for APCCC 2024. Thank you so much for being here with me today, Dan. Daniel Spratt: Thanks so much for having me. Alicia Morgans: Wonderful.
Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review
Abstract Biochemical recurrence (BCR) after primary definitive treatment for prostate cancer (PCa) is a heterogeneous disease state. While BCR is associated with worse oncologic outcomes, risk factors that impact outcomes can vary significantly, necessitating avenues for risk stratification. We sought to identify prognostic risk factors at the time of recurrence after primary radical prostatectomy or radiotherapy, and prior to salvage treatment(s), associated with adverse oncologic outcomes.
Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis
Abstract The utility of prostate radiotherapy (RT) is unclear in men with metastatic hormone-sensitive prostate cancer (mHSPC) receiving intensified systemic therapy with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs). We performed a network meta-analysis of randomized controlled trials (RCTs) to investigate the role of prostate RT in low-volume mHSPC.
Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis
Abstract The utility of prostate radiotherapy (RT) is unclear in men with metastatic hormone-sensitive prostate cancer (mHSPC) receiving intensified systemic therapy with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs). We performed a network meta-analysis of randomized controlled trials (RCTs) to investigate the role of prostate RT in low-volume mHSPC.
Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus
Article Dans Une Revue International Journal of Radiation Oncology, Biology, Physics Année : 2023 Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus Fichier principal 2023_Blanchard_IntJRadiatOncolBiolPhys.pdf (1.47 Mo) Télécharger le fichier Origine : Publication financée par une institution Licence : CC BY NC ND - Paternité - Pas d'utilisation commerciale - Pas de modification...
Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol
Prostate cancer is the most prevalent cancer in men and the second leading cause of cancer death in men in the USA. In 2023, American Cancer Society estimated 288,300 new prostate cancer cases (29% of male cancer cases), with 34,700 estimated deaths (11% of male cancer death) [1]. Prostate cancer incidence increases with increasing age, with the average age at the diagnosis time being 66 years.
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer
Key Points Question Is relugolix, an oral androgen deprivation therapy, safe and effective in patients receiving radiotherapy for prostate cancer? Findings In these 2 randomized clinical trials of 260 men with prostate cancer who were receiving treatment with radiotherapy and androgen deprivation therapy, relugolix achieved high castration rates in 95% or more of patients across localized, locally advanced, recurrent, and/or metastatic disease.
The Future of Prostate Cancer Treatment: An In-Depth Look at Emerging Personalized Strategies - Daniel Spratt
Read the Full Video Transcript Daniel Spratt: I did mention hormone therapy, a lot of guys, especially as we get into the higher grades, we give hormone therapy to. So what's coming very soon in this talk, there's a ton of work being done with this 22-gene classifier that I won't be talking about today.
The Current State of Radiation Oncology "Presentation" - Daniel Spratt
Read the Full Video Transcript Jason Hafron: I would like to introduce the speaker for our next session, What's New in Radiation Oncology, Dr. Dan Spratt. Dr. Spratt is the Chairman and Professor of Radiation Oncology at University Hospitals Seidman Cancer Center and Case Western Reserve University. He has published over 300 peer-reviewed manuscripts, including practice-changing work in the New England Journal, JAMA Lancet, JAMA Oncology, JCO.
What’s New in Radiation Oncology? Part 1 - Daniel Spratt
Read the Full Video Transcript Jason Hafron: I would like to introduce the speaker for our next session, What's New in Radiation Oncology, Dr. Dan Spratt. Dr. Spratt is the Chairman and Professor of Radiation Oncology at University Hospitals Seidman Cancer Center and Case Western Reserve University. He has published over 300 peer-reviewed manuscripts, including practice-changing work in the New England Journal, JAMA Lancet, JAMA Oncology, JCO.
What’s New in Radiation Oncology? Part 2 - Daniel Spratt
Read the Full Video Transcript Daniel Spratt: I did mention hormone therapy, a lot of guys, especially as we get into the higher grades, we give hormone therapy to. So what's coming very soon in this talk, there's a ton of work being done with this 22-gene classifier that I won't be talking about today.
What’s New in Radiation Oncology? Part 3 - Daniel Spratt
Read the Full Video Transcript Audience Member 1: Just one quick one. In the context of those folks getting SBRT in the advanced setting, the mCRPC, et cetera, they're getting other, oftentimes multiple, RLT therapies, they may have alphas, they may have betas, they may have SBRT. Some of our limiting issues really tend to be toxicity from a dose perspective, so how do we account and monitor that total dose per patient throughout their course? Daniel Spratt: Yeah, great question.
Correlation and Validation of Gene Expression Classifiers in Prostate Cancer: A Large-Scale Study - Daniel Spratt
Read the Full Video Transcript Aditya Bagrodia: Hi, my name's Aditya Bagrodia. I'm a urologic oncologist at UC San Diego Health. And it's a pleasure to talk with Dr. Dan Spratt, who's the Chairman at UH Seidman Cancer Center, Case Western Reserve University Department of Radiation Oncology. Dan, how are you doing today? Daniel Spratt: I'm doing fantastic. Thanks so much for having me. Aditya Bagrodia: Perfect. Perfect.
Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A Secondary Analysis of a Phase III Randomized Controlled Trial
ABSTRACT Pelvic radiotherapy may lead to decreased bone mineral density (BMD) and increased risk of fracture which could be of particular concern in prostate cancer (PCa) patients who also receive androgen deprivation therapy (ADT). We performed exploratory analysis of a randomized, double-blind, placebo-controlled trial to determine if exposure to prior pelvic external beam radiotherapy (XRT) affects BMD and risk of fracture in PCa patients treated with ADT.
FDA panel: Benefit of ‘highly anticipated’ lung cancer drug can’t be interpreted reliably
You've successfully added Hematology Oncology: Lung Cancer to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. An FDA advisory committee voted 10-2 that the results of a confirmatory trial for the targeted lung cancer drug sotorasib cannot be interpreted reliably.
The Artera AI Model: Advancing Personalized Medicine in Prostate Cancer Treatment | Dan Spratt & Alicia Morgans Discuss NEJM Evidence Manuscript
Read the Full Video Transcript Alicia Morgans: Hi, I'm so excited to be here with Daniel Spratt, a professor and radiation oncologist who's here to talk with me today about the Artera predictive model for prostate cancer. So excited to talk with you today. Daniel Spratt: Thank you. It's great to be here. Alicia Morgans: Great. I'm really excited to hear a little bit more about what you and the team published in the manuscript. Daniel Spratt: This is really exciting.
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial
Intermediate-risk prostate cancer is a heterogeneous disease state with diverse treatment options. The 22-gene Decipher genomic classifier (GC) retrospectively has shown to improve risk stratification in these patients. We assessed the performance of the GC in men with intermediate-risk disease enrolled in NRG Oncology/RTOG 01-26 with updated follow-up.
Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer | Prostate Cancer and Prostatic Diseases
Abstract Genomic classifiers are endorsed by guidelines and commonly used to inform prognosis in prostate cancer. We aimed to understand the distribution of genomic risk within the validated staging collaboration for cancer of the prostate (STAR-CAP) and propose a system integrating genomic and clinicopathologic risk. We hypothesized that genomic heterogeneity would have implications on risk estimates and may inform treatment decisions.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Daniel E.
Contact Daniel E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack